The share price of the cellular oncology drug developer, which counts Novartis, Johnson & Johnson and PureTech Health as investors, has doubled since it floated.

Vor Biopharma, a US-based cancer therapy developer backed by pharmaceutical firms Novartis, Johnson & Johnson and PureTech Health, has gone public in a $177m initial public offering. The company issued 9.83 million shares – increased from 8.8 million – on the Nasdaq Global Select Market priced at $18.00 each, at the top of the IPO’s…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.